Meta-Analysisvery high evidence
Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.
Lancet (London, England)·February 14, 2026·PMID 41655587
Why it mattersStatin product labels list many adverse effects based on lower-quality evidence, potentially deterring appropriate use. This large, rigorous analysis clarifies which effects are truly attributable to statins, enabling more accurate risk-benefit discussions and reducing unnecessary discontinuation.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled